| Identification | Back Directory | [Name]
Eribaxaban | [CAS]
536748-46-6 | [Synonyms]
PD348292
PD-348292
PD 348292
PD0348292
Eribaxaban
PD 0348292)
Eribaxaban
(PD-0348292
(2R,4R)-1-N-(4-chlorophenyl)-2-N-[2-fluoro-4-(2-oxopyridin-1-yl)phenyl]-4-methoxypyrrolidine-1,2-dicarboxamide | [Molecular Formula]
C24H22ClFN4O4 | [MDL Number]
MFCD27665449 | [MOL File]
536748-46-6.mol | [Molecular Weight]
484.907 |
| Hazard Information | Back Directory | [Uses]
Eribaxaban (PD-0348292) is an orally active and selective FXa inhibitor with a Ki value of 0.32 nM. Eribaxaban reduces thrombus formation[1][2]. | [Definition]
ChEBI: Eribaxaban is a member of the class of pyrrolidines that is (2R,4R)-N(1)-(p-chlorophenyl)-4-methoxypyrrolidine-1,2-dicarboxamide in which the nitrogen of the 2-carbamoyl group has been substituted by a 2-fluoro-4-(2-oxopyridin-1(2H)-yl)phenyl group. It is a synthetic organic anticoagulant compound that targets activated factor Xa in the coagulation cascade. It has a role as an anticoagulant, an EC 3.4.21.6 (coagulation factor Xa) inhibitor and a serine protease inhibitor. It is a pyridone, a secondary carboxamide, a member of ureas, a member of monochlorobenzenes, a member of pyrrolidines and a member of monofluorobenzenes. | [in vivo]
Eribaxaban (0.4, 0.9, 4.3 mg/kg; p.o.) reduces platelet-rich thrombus formation[2]. | Animal Model: | Four-month-old, pre-estrus, female pigs[2] | | Dosage: | 0.4, 0.9, 4.3 mg/kg | | Administration: | P.o.; four hours prior to thrombus induction | | Result: | Significantly reducted carotid platelet deposition, chamber platelet deposition. |
| [References]
[1] Eriksson BI, et al. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Clin Pharmacokinet. 2009;48(1):1-22. DOI:10.2165/0003088-200948010-00001
[2] Karnicki K, et al. Comparison of PD0348292, a selective factor Xa inhibitor, to antiplatelet agents for the inhibition of arterial thrombosis. Thromb Haemost. 2008 Apr;99(4):759-66. DOI:10.1160/TH07-09-0576 |
|
|